Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma

Catholic University, Italy

Status: Completed

Conditions: Asthma

Treatments: Drug: Formoterol

Study type: Observational

Funder types: Other

Identifiers

NCT01786616

UCSC-AG-16

Details and patient eligibility

About

Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.

Enrollment: 30 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild to moderate asthma
• Stable clinical conditions

Exclusion criteria

• Smokers
• Current therapy with oral steroids
• Exacerbations within the past 3 months

Trial design

30 participants in 1 patient group

Formoterol

Description:

12 mcg BID for four weeks

Treatment:

Drug: Formoterol